个人中心 - 老虎社区

CcccL

IP属地：未知

帖子 · 204帖子 · 204
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- CcccLCcccL
  ·2021-12-17
  Hello! 👋🏻
  990 评论
  点赞
  分享
  举报
- CcccLCcccL
  ·2021-12-17
  Jia lat
  非常抱歉，此主贴已删除
  1,211 评论
  点赞
  分享
  举报
- CcccLCcccL
  ·2021-11-30
  Confusing. A lot of uncertainty
  Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates
  Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant A
  Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates
  1,157 2
  2
  分享
  举报
- CcccLCcccL
  ·2021-11-22
  Everyone wants to go out. Tired of staying at home. More firms prefer Worker’s at office. Zoom will not be popular in future
  Zoom Reports Earnings Monday. Here’s What to Expect.
  Zoom Video Communications stock remains under considerable selling pressure, as investors adjust the
  Zoom Reports Earnings Monday. Here’s What to Expect.
  1,227 1
  3
  分享
  举报
- CcccLCcccL
  ·2021-11-22
  Nothing wrong to support forms that have unionized workers. Tesla should just allow their workers to unionizedrather than just focus on maximizing profits at the expense of workers.
  非常抱歉，此主贴已删除
  1,162 1
  4
  分享
  举报
- CcccLCcccL
  ·2021-08-27
  This is good for the consumers
  非常抱歉，此主贴已删除
  627 评论
  1
  分享
  举报
- CcccLCcccL
  ·2021-08-22
  This is from the filing for Q2. It could have changed already because it is now Q3
  非常抱歉，此主贴已删除
  750 1
  8
  分享
  举报
- CcccLCcccL
  ·2021-07-28
  Wow that is a lot
  非常抱歉，此主贴已删除
  835 1
  3
  分享
  举报
- CcccLCcccL
  ·2021-07-23
  How long till singapore can open up? Retail is not doing well
  非常抱歉，此主贴已删除
  520 1
  2
  分享
  举报
- CcccLCcccL
  ·2021-06-26
  Wow!
  非常抱歉，此主贴已删除
  597 评论
  2
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3566877420609993","uuid":"3566877420609993","gmtCreate":1603804640776,"gmtModify":1611540223391,"name":"CcccL","pinyin":"ccccl","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":17,"headSize":97,"tweetSize":204,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.12","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.22","exceedPercentage":"93.74%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.27%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":699028162,"gmtCreate":1639725624800,"gmtModify":1639725624987,"author":{"id":"3566877420609993","authorId":"3566877420609993","name":"CcccL","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566877420609993","authorIdStr":"3566877420609993"},"themes":[],"htmlText":"Hello! 👋🏻","listText":"Hello! 👋🏻","text":"Hello! 👋🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699028162","isVote":1,"tweetType":1,"viewCount":990,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690504803,"gmtCreate":1639676762903,"gmtModify":1639676763103,"author":{"id":"3566877420609993","authorId":"3566877420609993","name":"CcccL","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566877420609993","authorIdStr":"3566877420609993"},"themes":[],"htmlText":"Jia lat","listText":"Jia lat","text":"Jia lat","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690504803","repostId":"2192994932","repostType":2,"isVote":1,"tweetType":1,"viewCount":1211,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609688107,"gmtCreate":1638279096921,"gmtModify":1638279097066,"author":{"id":"3566877420609993","authorId":"3566877420609993","name":"CcccL","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566877420609993","authorIdStr":"3566877420609993"},"themes":[],"htmlText":"Confusing. A lot of uncertainty&nbsp;","listText":"Confusing. A lot of uncertainty&nbsp;","text":"Confusing. A lot of uncertainty","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/609688107","repostId":"1192203085","repostType":2,"repost":{"id":"1192203085","kind":"news","pubTimestamp":1638273550,"share":"https://www.laohu8.com/m/news/1192203085?lang=&edition=full","pubTime":"2021-11-30 19:59","market":"us","language":"en","title":"Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates","url":"https://stock-news.laohu8.com/highlight/detail?id=1192203085","media":"The Wall Street Journal","summary":"Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA ","content":"<p>Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ed6086131617e6933fe07f3e46cd5c26\" tg-width=\"1290\" tg-height=\"859\" referrerpolicy=\"no-referrer\"><span>A monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.</span></p>\n<p>Preliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.</p>\n<p>Separate testing of another authorized Covid-19 antibody drug cocktail, from&nbsp;Eli Lilly&amp; Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.</p>\n<p>The findings are the early results of researchers’ race to assess the impact of the&nbsp;new Omicron variant&nbsp;on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.</p>\n<p>Researchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.</p>\n<p>Monoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.</p>\n<p>They are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.</p>\n<p>The drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former&nbsp;President Donald Trump credited Regeneron’s drug&nbsp;with his speedy recovery from Covid-19.</p>\n<p>Regeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6e7fac5c4630025e6c5ad28d2c3efbfa\" tg-width=\"1050\" tg-height=\"700\" referrerpolicy=\"no-referrer\"><span>Antiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.</span></p>\n<p>If final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.</p>\n<p>One of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.</p>\n<p>The Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.</p>\n<p>“What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”</p>\n<p>Scientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.</p>\n<p>More comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.</p>\n<p>Lilly is in the process of testing the new variant against its drug, a combination of&nbsp;two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.</p>\n<p>She declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.</p>\n<p>“I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”</p>\n<p>A rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including&nbsp;Vir Biotechnology&nbsp;Inc.&nbsp;and GlaxoSmithKline PLC, whose drug&nbsp;sotrovimab was authorized for emergency use&nbsp;earlier this year.</p>\n<p>Fred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.</p>\n<p>Adagio Therapeutics&nbsp;Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.</p>\n<p>Vir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.</p>\n<p>Omicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.</p>\n<p>Vir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.</p>\n<p>“They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.</p>\n<p>It will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.</p>\n<p>“Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”</p>\n<p>Antiviral drugs, including pills from&nbsp;Merck&amp; Co. and partner Ridgeback Biotherapeutics LP and from&nbsp;Pfizer&nbsp;Inc.&nbsp;that are being&nbsp;evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.</p>\n<p>Doctors and patients have been looking forward to authorization of the pills, which in clinical trials have&nbsp;reduced the risk of hospitalization&nbsp;if taken early enough.</p>\n<p>“The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.</p>\n<p>Pfizer and Merck said they expect their drugs to be effective against Omicron.</p>\n<p>Gilead SciencesInc.&nbsp;also said it expects&nbsp;Veklury, its antiviral drug&nbsp;used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Covid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCovid-19 Antibody Drugs Are Challenged by Omicron, Preliminary Testing Indicates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 19:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.\nPreliminary tests ...</p>\n\n<a href=\"https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","REGN":"再生元制药公司"},"source_url":"https://www.wsj.com/articles/covid-19-antibody-drugs-are-challenged-by-omicron-preliminary-testing-indicates-11638270003?mod=Searchresults_pos1&page=1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192203085","content_text":"Regeneron said its antibody drug cocktail was found to lose effectiveness against the new variant\nA monoclonal antibody treatment site in Pembroke Pines, Fla., earlier this year.\nPreliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc. loses effectiveness against Omicron, the company said Tuesday, a sign that some products in an important class of therapies might need modifying if the new strain becomes widespread.\nSeparate testing of another authorized Covid-19 antibody drug cocktail, from Eli Lilly& Co., indicates it also isn’t as effective against Omicron, outside scientists said. Lilly said it is testing the new variant against its antibody treatment and wouldn’t speculate on what the results will be.\nThe findings are the early results of researchers’ race to assess the impact of the new Omicron variant on Covid-19 treatments that patients, doctors and hospitals have been relying on, as well as pills in development that have promised to keep people out of the hospital.\nResearchers say some antibody therapies are likely to be especially vulnerable to Omicron because it contains mutations to the spike protein that the Regeneron and Lilly drugs target, while other drugs should hold up well because they attack elements of the virus unchanged in the variant.\nMonoclonal antibodies are lab-made molecules derived from survivors of Covid-19 or mice engineered to have human immune systems. When given soon after infection, the drugs attach to the surface of the coronavirus and prevent it from replicating itself in new cells.\nThey are the only drugs authorized to treat patients, before they require hospitalization, who are at high risk of developing severe cases.\nThe drugs differ from vaccines, which train the immune system how to defend against the virus, including with the production of antibodies. Last year, former President Donald Trump credited Regeneron’s drug with his speedy recovery from Covid-19.\nRegeneron said it would be able to quantify the impact of the variant in coming weeks, after further testing is done.\nAntiviral pills such as Pfizer’s Paxlovid appear to be unaffected by the variant.\nIf final testing shows that its antibody drugs are less effective against Omicron, Regeneron has developed alternative antibodies that it can push into clinical testing and that it thinks will retain effectiveness against the variant, said George Yancopoulos, the company’s president and chief scientific officer.\nOne of Regeneron’s alternative antibodies is already in clinical testing, which the company began in anticipation of new variants emerging over time.\nThe Omicron variant was identified last week by scientists in South Africa, prompting drug researchers to scramble to see if the relatively small medicine chest of Covid-19 treatments would still work against the new strain if it ends up spreading widely.\n“What we have to admit is, in the course of the past six days, our urgency has increased,” Dr. Yancopoulos said in an interview. “What started out as a backup plan has now been made a lot more urgent.”\nScientists at the Fred Hutchinson Cancer Research Center in Seattle found that individual mutations from Omicron reduced or eliminated the ability of Regeneron’s and Lilly’s drugs to attach to the virus, said Allie Greaney, a Ph.D. candidate at the center and the University of Washington in Seattle.\nMore comprehensive tests of the drugs against the entire variant are needed to fully understand the impact, she said. “I’m not certain what the exact magnitude of effect would be, but probably less effective,” said Ms. Greaney.\nLilly is in the process of testing the new variant against its drug, a combination of two antibodies called bamlanivimab and etesevimab,said Nicole Kallewaard, a Lilly virologist and research adviser.\nShe declined to comment on the results showing reduced effectiveness against individual Omicron mutations, because the results may differ when all of the mutations are combined.\n“I think that we need to wait for confirmation of the whole virus,” said Dr. Kallewaard. “Hopefully, the data will come in the next few weeks.”\nA rise in the prevalence of Omicron could present an opportunity for competitors who say their drugs don’t appear in preliminary testing to be affected by the variant, including Vir Biotechnology Inc. and GlaxoSmithKline PLC, whose drug sotrovimab was authorized for emergency use earlier this year.\nFred Hutchinson researchers also said their initial testing indicated the Vir-GSK antibody drug retained its effectiveness.\nAdagio Therapeutics Inc.,a biotech with a Covid-19 antibody drug in clinical trials, said its antibody also appears to be unaffected by the new variant.\nVir, Glaxo and Adagio said they are conducting further tests to confirm that their drugs aren’t affected by Omicron.\nOmicron poses a threat to lab-made antibody drugs as well as antibodies generated by vaccines, because the new variant has mutations on the spike protein part of the virus where antibodies are known to frequently attach themselves, scientists say.\nVir and Adagio officials said the companies designed their antibodies with the aim of targeting spots on the virus that are common across different coronaviruses that remained stable even after numerous mutations over many years.\n“They bind to a region of the virus that through decades of evolution has not changed a lot,” Adagio Chief Executive Tillman Gerngross said in an interview. “Those conserved areas make the virus much more vulnerable” to antibodies.\nIt will take at least two weeks to create a version of the full Omicron virus variant and test antibody drugs against it, company officials said. Still, scientists say they are concerned by what they know already about the variant’s ability to evade antibodies produced by vaccines, prior infection or from drug treatment.\n“Omicron hasn’t become the next Delta,” Vir Chief Scientific Officer Skip Virgin said in an interview. But “we think the extent of the mutations, the number of them, means that the world needs to take Omicron very seriously.”\nAntiviral drugs, including pills from Merck& Co. and partner Ridgeback Biotherapeutics LP and from Pfizer Inc. that are being evaluated for authorization,appear to be unaffected by the variant because they target a different site on the virus, said Michel Nussenzweig, an immunologist at Rockefeller University.\nDoctors and patients have been looking forward to authorization of the pills, which in clinical trials have reduced the risk of hospitalization if taken early enough.\n“The targets of the pills appear to be under less pressure and may be OK, but this too needs to be tested,” said Dr. Nussenzweig.\nPfizer and Merck said they expect their drugs to be effective against Omicron.\nGilead SciencesInc. also said it expects Veklury, its antiviral drug used to treat hospitalized patients, to retain effectiveness against Omicron as it has against other variants of concern.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1157,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872444051,"gmtCreate":1637566225446,"gmtModify":1637566889991,"author":{"id":"3566877420609993","authorId":"3566877420609993","name":"CcccL","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566877420609993","authorIdStr":"3566877420609993"},"themes":[],"htmlText":"Everyone wants to go out. Tired of staying at home. More firms prefer Worker’s at office.&nbsp;Zoom will not be popular in future","listText":"Everyone wants to go out. Tired of staying at home. More firms prefer Worker’s at office.&nbsp;Zoom will not be popular in future","text":"Everyone wants to go out. Tired of staying at home. More firms prefer Worker’s at office. Zoom will not be popular in future","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/872444051","repostId":"1141390597","repostType":2,"repost":{"id":"1141390597","kind":"news","pubTimestamp":1637536472,"share":"https://www.laohu8.com/m/news/1141390597?lang=&edition=full","pubTime":"2021-11-22 07:14","market":"us","language":"en","title":"Zoom Reports Earnings Monday. Here’s What to Expect.","url":"https://stock-news.laohu8.com/highlight/detail?id=1141390597","media":"Barrons","summary":"Zoom Video Communications stock remains under considerable selling pressure, as investors adjust the","content":"<p>Zoom Video Communications&nbsp;stock remains under considerable selling pressure, as investors adjust their thinking on the videoconferencing company as its growth rate continues to ebb and the world emerges from the pandemic.</p>\n<p>Zoom (ticker: ZM) reports financial results after the close of trading on Monday. For the fiscal third quarter through Oct. 31, the company has projected revenue of $1.02 billion, with non-GAAP earnings of $1.07 to $1.08 a share. Street estimates call for $1.02 billion and $1.09 a share.</p>\n<p>Zoom shares have fallen 28% since the company reported results for the July quarter, reflecting growing concerns about both slowing growth and increased competition from other players in the videoconferencing space, in particular Microsoft Teams. Since Zoom last reported financial results, the company suffered the collapse of its proposed acquisition of the call-center software operator&nbsp;Five9&nbsp;(FIVN).</p>\n<p>With its core videoconferencing business under pressure, Zoom has been pushing more aggressively into new areas, in particular Zoom Phone, the company’s cloud-based telephony business. But competition in that market remains fierce, from&nbsp;RingCentral&nbsp;and others. At the same time, there are concerns that usage of the core Zoom service is falling as schools and businesses reopen, reducing the need to be in Zoom meetings throughout the day.</p>\n<p>Citi analyst Tyler Radke wrote in a research note last week that the setup for Zoom’s earnings looks mixed. “Potential headwinds from reopening churn and summer seasonality” are likely to limit revenue upside, he said.</p>\n<p>However, Radke also notes that “sentiment is quite negative,” and that guidance was relatively conservative—he sees potential for a 2% to 3% beat on the revenue line. That said, Radke also says Zoom is unlikely to aggressively raise full-year guidance “given few signs of incremental improvement” in the business.</p>\n<p>Radke maintains his Neutral rating and $304 target on the stock, anticipating that the company’s growth rate is headed to below 20% in fiscal 2023 and beyond. And he sees the opportunities in Phone and other areas as small, and “likely unable to offset a larger-scale deceleration” in the core video meetings segment.</p>\n<p>Morgan Stanley analyst Meta Marshall is more upbeat. She maintains an Overweight rating on the stock, though she trimmed her target price this week to $365, from $400. She thinks the Street has overly discounted Zoom’s enterprise business, and says the company remains in the early days of a $70 billion opportunity in unified communications. Any signs of weakness in the small- and medium-size business market could pressure the stock, she warns, but adds that she would be a buyer on any weakness connected with earnings.</p>\n<p>For the fiscal fourth quarter ending in January, the Street consensus calls for revenue of $1.02 billion and profits of $1.09 a share. Zoom last quarter projected fiscal 2022 full-year revenue of $4.01 billion to $4.02 billion, with earnings of $4.75 to $4.79 a share.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zoom Reports Earnings Monday. Here’s What to Expect.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZoom Reports Earnings Monday. Here’s What to Expect.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-22 07:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/zoom-stock-earnings-preview-51637356886?mod=hp_LEADSUPP_2><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zoom Video Communications stock remains under considerable selling pressure, as investors adjust their thinking on the videoconferencing company as its growth rate continues to ebb and the world ...</p>\n\n<a href=\"https://www.barrons.com/articles/zoom-stock-earnings-preview-51637356886?mod=hp_LEADSUPP_2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZM":"Zoom"},"source_url":"https://www.barrons.com/articles/zoom-stock-earnings-preview-51637356886?mod=hp_LEADSUPP_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141390597","content_text":"Zoom Video Communications stock remains under considerable selling pressure, as investors adjust their thinking on the videoconferencing company as its growth rate continues to ebb and the world emerges from the pandemic.\nZoom (ticker: ZM) reports financial results after the close of trading on Monday. For the fiscal third quarter through Oct. 31, the company has projected revenue of $1.02 billion, with non-GAAP earnings of $1.07 to $1.08 a share. Street estimates call for $1.02 billion and $1.09 a share.\nZoom shares have fallen 28% since the company reported results for the July quarter, reflecting growing concerns about both slowing growth and increased competition from other players in the videoconferencing space, in particular Microsoft Teams. Since Zoom last reported financial results, the company suffered the collapse of its proposed acquisition of the call-center software operator Five9 (FIVN).\nWith its core videoconferencing business under pressure, Zoom has been pushing more aggressively into new areas, in particular Zoom Phone, the company’s cloud-based telephony business. But competition in that market remains fierce, from RingCentral and others. At the same time, there are concerns that usage of the core Zoom service is falling as schools and businesses reopen, reducing the need to be in Zoom meetings throughout the day.\nCiti analyst Tyler Radke wrote in a research note last week that the setup for Zoom’s earnings looks mixed. “Potential headwinds from reopening churn and summer seasonality” are likely to limit revenue upside, he said.\nHowever, Radke also notes that “sentiment is quite negative,” and that guidance was relatively conservative—he sees potential for a 2% to 3% beat on the revenue line. That said, Radke also says Zoom is unlikely to aggressively raise full-year guidance “given few signs of incremental improvement” in the business.\nRadke maintains his Neutral rating and $304 target on the stock, anticipating that the company’s growth rate is headed to below 20% in fiscal 2023 and beyond. And he sees the opportunities in Phone and other areas as small, and “likely unable to offset a larger-scale deceleration” in the core video meetings segment.\nMorgan Stanley analyst Meta Marshall is more upbeat. She maintains an Overweight rating on the stock, though she trimmed her target price this week to $365, from $400. She thinks the Street has overly discounted Zoom’s enterprise business, and says the company remains in the early days of a $70 billion opportunity in unified communications. Any signs of weakness in the small- and medium-size business market could pressure the stock, she warns, but adds that she would be a buyer on any weakness connected with earnings.\nFor the fiscal fourth quarter ending in January, the Street consensus calls for revenue of $1.02 billion and profits of $1.09 a share. Zoom last quarter projected fiscal 2022 full-year revenue of $4.01 billion to $4.02 billion, with earnings of $4.75 to $4.79 a share.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1227,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872446427,"gmtCreate":1637566000969,"gmtModify":1637566001105,"author":{"id":"3566877420609993","authorId":"3566877420609993","name":"CcccL","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566877420609993","authorIdStr":"3566877420609993"},"themes":[],"htmlText":"Nothing wrong to support forms that have unionized workers.&nbsp;Tesla should just allow their workers to unionizedrather than just focus on maximizing profits at the expense of&nbsp;workers.","listText":"Nothing wrong to support forms that have unionized workers.&nbsp;Tesla should just allow their workers to unionizedrather than just focus on maximizing profits at the expense of&nbsp;workers.","text":"Nothing wrong to support forms that have unionized workers. Tesla should just allow their workers to unionizedrather than just focus on maximizing profits at the expense of workers.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/872446427","repostId":"1159391988","repostType":4,"isVote":1,"tweetType":1,"viewCount":1162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":819858039,"gmtCreate":1630057303421,"gmtModify":1704955294406,"author":{"id":"3566877420609993","authorId":"3566877420609993","name":"CcccL","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566877420609993","authorIdStr":"3566877420609993"},"themes":[],"htmlText":"This is good for the consumers&nbsp;","listText":"This is good for the consumers&nbsp;","text":"This is good for the consumers","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/819858039","repostId":"2162301220","repostType":2,"isVote":1,"tweetType":1,"viewCount":627,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":832292155,"gmtCreate":1629634342577,"gmtModify":1631890014949,"author":{"id":"3566877420609993","authorId":"3566877420609993","name":"CcccL","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566877420609993","authorIdStr":"3566877420609993"},"themes":[],"htmlText":"This is from the filing for Q2. It could have changed already because it is now Q3","listText":"This is from the filing for Q2. It could have changed already because it is now Q3","text":"This is from the filing for Q2. It could have changed already because it is now Q3","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/832292155","repostId":"1133515985","repostType":4,"isVote":1,"tweetType":1,"viewCount":750,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801034666,"gmtCreate":1627471895155,"gmtModify":1631890014949,"author":{"id":"3566877420609993","authorId":"3566877420609993","name":"CcccL","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566877420609993","authorIdStr":"3566877420609993"},"themes":[],"htmlText":"Wow that is a lot","listText":"Wow that is a lot","text":"Wow that is a lot","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/801034666","repostId":"2154386941","repostType":2,"isVote":1,"tweetType":1,"viewCount":835,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":175678219,"gmtCreate":1627031088631,"gmtModify":1631890014951,"author":{"id":"3566877420609993","authorId":"3566877420609993","name":"CcccL","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566877420609993","authorIdStr":"3566877420609993"},"themes":[],"htmlText":"How long till singapore can open up? Retail is not doing well","listText":"How long till singapore can open up? Retail is not doing well","text":"How long till singapore can open up? Retail is not doing well","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/175678219","repostId":"1133956405","repostType":4,"isVote":1,"tweetType":1,"viewCount":520,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":125331641,"gmtCreate":1624649879683,"gmtModify":1631890014957,"author":{"id":"3566877420609993","authorId":"3566877420609993","name":"CcccL","avatar":"https://static.tigerbbs.com/27eb54773a8f0b3851def7cabc15cb0e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566877420609993","authorIdStr":"3566877420609993"},"themes":[],"htmlText":"Wow!","listText":"Wow!","text":"Wow!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/125331641","repostId":"2146076005","repostType":2,"isVote":1,"tweetType":1,"viewCount":597,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}